Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast In Primary Sclerosing Cholangitis To Be Highlighted In An Oral Late-Breaking Presentation At The Liver Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics, Inc. (NASDAQ:PLRX) has announced a late-breaking presentation of results from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) at The Liver Meeting® 2023. Bexotegrast is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis (IPF) and PSC. The company is pleased with the positive interim results and looks forward to further investigation of bexotegrast, including 12 week data from the 320 mg dose in the first quarter of 2024 and 24 week safety data in mid-2024.
October 19, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pliant Therapeutics' positive interim results from the INTEGRIS-PSC Phase 2a trial of bexotegrast could potentially boost investor confidence in the company's research and development capabilities. The company's announcement of further investigation of bexotegrast in 2024 also indicates a commitment to the development of this drug, which could have a positive impact on the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. The announcement of further investigation of bexotegrast in 2024 also signals the company's commitment to the development of this drug, which could be seen as a positive sign by investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100